Abstract
Pituitary adenomas may hypersecrete hormones (including prolactin, growth hormone and adrenocorticotropic hormone, and rarely follicle-stimulating hormone, luteinizing hormone or TSH) or may be nonfunctional. Despite their high prevalence in the general population, these tumors are invariably benign and exhibit features of differentiated pituitary cell function as well as premature proliferative arrest. Pathogenesis of dysregulated pituitary cell proliferation and unrestrained hormone hypersecretion may be mediated by hypothalamic, intrapituitary and/or peripheral factors. Altered expression of pituitary cell cycle genes, activation of pituitary selective oncoproteins or loss of pituitary suppressor factors may be associated with aberrant growth factor signaling. Considerable information on the etiology of these tumors has been derived from transgenic animal models, which may not accurately and universally reflect human tumor pathophysiology. Understanding subcellular mechanisms that underlie pituitary tumorigenesis will enable development of tumor aggression markers as well as novel targeted therapies.
Key Points
-
Pituitary cell growth and hormone synthesis are controlled by hypothalamic, intrapituitary and peripheral factors
-
Pituitary tumors arising from differentiated hormone-expressing cells are commonly encountered and are invariably benign
-
Adenomas may secrete one or more hormones including prolactin, growth hormone, adrenocorticotropic hormone, glycoprotein gonadotroph subunits or hormones, or TSH; most are nonsecreting with no obvious peripheral clinical phenotype
-
The pathogenetic mechanisms that underlie pituitary tumorigenesis may be genetic or epigenetic and result in cell cycle dysregulation, signaling defects or loss of tumor suppressor factors
-
Rarely, patients present with pituitary tumors that are components of familial genetic syndromes
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Change history
01 April 2011
In the version of this article initially published online, there was an error in the penultimate sentence of page 4. This sentence should have read 'Pttg was isolated from rat pituitary tumor cells by differential RNA display with normal pituitary glands, and is also induced by the E2F transcription factor in the pituitary gland.45,46' The error has been corrected for the print, HTML and PDF versions of the article.
References
Melmed, S. Mechanisms for pituitary tumorigenesis: the plastic pituitary. J. Clin. Invest. 112, 1603–1618 (2003).
Levy, A. & Lightman, S. Molecular defects in the pathogenesis of pituitary tumours. Front. Neuroendocrinol. 24, 94–127 (2003).
Scully, K. M. & Rosenfeld, M. G. Pituitary development: regulatory codes in mammalian organogenesis. Science 295, 2231–2235 (2002).
Keegan, C. E. & Camper, S. A. Mouse knockout solves endocrine puzzle and promotes new pituitary lineage model. Genes Dev. 17, 677–682 (2003).
Drouin, J. Molecular mechanisms of pituitary differentiation and regulation: implications for hormone deficiencies and hormone resistance syndromes. Front. Horm. Res. 35, 74–87 (2006).
Mehta, A. & Dattani, M. T. Developmental disorders of the hypothalamus and pituitary gland associated with congential hypopituitarism. Best Pract. Res. Clin. Endocrinol. Metab. 22, 191–206 (2007).
Li, X., Perissi, V., Liu, F., Rose, D. W. & Rosenfeld, M. G. Tissue-specific regulation of retinal and pituitary precursor cell proliferation. Science 297, 1180–1183 (2002).
Romero, C. J., Nesi-Franca, S. & Radovick, S. The molecular basis of hypopituitarism. Trends Endocrinol. Metab. 20, 506–516 (2009).
Moons, D. S. et al. Pituitary hypoplasia and lactotroph dysfunction in mice deficient for cyclin-dependent kinase-4. Endocrinology 143, 3001–3008 (2002).
Wang, Z., Yu, R. & Melmed, S. Mice lacking pituitary tumor transforming gene show testicular and splenic hypoplasia, thymic hyperplasia, thrombocytopenia, aberrant cell cycle progression, and premature centromere division. Mol. Endocrinol. 15, 1870–1879 (2001).
Al-Gahtany, M., Horvath, E. & Kovacs, K. Pituitary hyperplasia. Hormones (Athens) 2, 149–158 (2003).
Ben-Jonathan, N. & Liu, J. W. Pituitary lactotrophs: endocrine, paracrine, juxtacrine, and autocrine interactions. Trends Endocrinol. Metab. 3, 254–258 (1992).
Heaney, A. P., Horwitz, G. A., Wang, Z., Singson, R. & Melmed, S. Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis. Nat. Med. 5, 1317–1321 (1999).
Alkhani, A. M. et al. Cytology of pituitary thyrotroph hyperplasia in protracted primary hypothyroidism. Pituitary 1, 291–295 (1999).
Herman, V., Fagin, J., Gonsky, R., Kovacs, K. & Melmed, S. Clonal origin of pituitary adenomas. J. Clin. Endocrinol. Metab. 71, 1427–1433 (1990).
Gleiberman, A. S. et al. Genetic approaches identify adult pituitary stem cells. Proc. Natl Acad. Sci. USA 105, 6332–6337 (2008).
Fauquier, T., Rizzoti, K., Dattani, M., Lovell-Badge, R. & Robinson, I. C. SOX2-expressing progenitor cells generate all of the major cell types in the adult mouse pituitary gland. Proc. Natl Acad. Sci. USA 105, 2907–2912 (2008).
Hosoyama, T. et al. A postnatal pax7 progenitor gives rise to pituitary adenomas. Genes Cancer 1, 388–402 (2010).
Fernandez, A., Karavitaki, N. & Wass, J. A. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin. Endocrinol. (Oxf.) 72, 377–382 (2010).
Daly, A. F. et al. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J. Clin. Endocrinol. Metab. 91, 4769–4775 (2006).
Raappana, A., Koivukangas, J., Ebeling, T. & Pirila, T. Incidence of pituitary adenomas in Northern Finland in 1992–2007. J. Clin. Endocrinol. Metab. 95, 4268–4275 (2010).
Kovacs, K., Horvath, E. & Vidal, S. Classification of pituitary adenomas. J. Neurooncol. 54, 121–127 (2001).
Al-Brahim, N. Y. & Asa, S. L. My approach to pathology of the pituitary gland. J. Clin. Pathol. 59, 1245–1253 (2006).
Cooper, O. et al. Silent corticogonadotroph adenomas: clinical and cellular characteristics and long-term outcomes. Horm. Cancer 1, 80–92 (2010).
Ben-Shlomo, A. & Melmed, S. Pituitary somatostatin receptor signaling. Trends Endocrinol. Metab. 21, 123–133 (2010).
Melmed, S. Acromegaly pathogenesis and treatment. J. Clin. Invest. 119, 3189–3202 (2009).
Jacks, T. et al. Effects of an Rb mutation in the mouse. Nature 359, 295–300 (1992).
Kiyokawa, H. et al. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). Cell 85, 721–732 (1996).
Abbud, R. A. et al. Early multipotential pituitary focal hyperplasia in the alpha-subunit of glycoprotein hormone-driven pituitary tumor-transforming gene transgenic mice. Mol. Endocrinol. 19, 1383–1391 (2005).
Ewing, I. et al. A mutation and expression analysis of the oncogene BRAF in pituitary adenomas. Clin. Endocrinol. (Oxf.) 66, 348–352 (2007).
Asa, S. L. & Ezzat, S. The pathogenesis of pituitary tumors. Annu. Rev. Pathol. 4, 97–126 (2009).
Galland, F. et al. Differential gene expression profiles of invasive and non-invasive non-functioning pituitary adenomas based on microarray analysis. Endocr. Relat. Cancer 17, 361–371 (2010).
Moreno, C. S. et al. Novel molecular signaling and classification of human clinically nonfunctional pituitary adenomas identified by gene expression profiling and proteomic analyses. Cancer Res. 65, 10214–10222 (2005).
Zhan, X. & Desiderio, D. M. Signaling pathway networks mined from human pituitary adenoma proteomics data. BMC Med. Genomics 3, 13 (2010).
Tanase, C. P., Neagu, M. & Albulescu, R. Key signaling molecules in pituitary tumors. Expert Rev. Mol. Diagn. 9, 859–877 (2009).
Attwooll, C., Lazzerini Denchi, E. & Helin, K. The E2F family: specific functions and overlapping interests. EMBO J. 23, 4709–4716 (2004).
Lazzerini Denchi, E., Attwooll, C., Pasini, D. & Helin, K. Deregulated E2F activity induces hyperplasia and senescence-like features in the mouse pituitary gland. Mol. Cell Biol. 25, 2660–2672 (2005).
Simpson, D. J., Hibberts, N. A., McNicol, A. M., Clayton, R. N. & Farrell, W. E. Loss of pRb expression in pituitary adenomas is associated with methylation of the RB1 CpG island. Cancer Res. 60, 1211–1216 (2000).
Simpson, D. J. et al. Molecular pathology shows p16 methylation in nonadenomatous pituitaries from patients with Cushing's disease. Clin. Cancer Res. 10, 1780–1788 (2004).
Hossain, M. G. et al. Expression of p18(INK4C) is down-regulated in human pituitary adenomas. Endocr. Pathol. 20, 114–121 (2009).
Roussel-Gervais, A. et al. Cooperation between Cyclin E and p27(Kip1) in pituitary tumorigenesis. Mol. Endocrinol. 24, 1835–1845 (2010).
Alexandraki, K. I. & Grossman, A. B. Novel insights in the diagnosis of Cushing's syndrome. Neuroendocrinology 92 (Suppl. 1), 35–43 (2010).
Bilodeau, S. et al. Role of Brg1 and HDAC2 in GR trans-repression of the pituitary POMC gene and misexpression in Cushing disease. Genes Dev. 20, 2871–2886 (2006).
Bellodi, C. et al. Loss of function of the tumor suppressor DKC1 perturbs p27 translation control and contributes to pituitary tumorigenesis. Cancer Res. 70, 6026–6035 (2010).
Pei, L. & Melmed, S. Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Mol. Endocrinol. 11, 433–441 (1997).
Zhou, C., Wawrowsky, K., Bannykh, S., Gutman, S. & Melmed, S. E2F1 induces pituitary tumor transforming gene (PTTG1) expression in human pituitary tumors. Mol. Endocrinol. 23, 2000–2012 (2009).
Zou, H., McGarry, T. J., Bernal, T. & Kirschner, M. W. Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science 285, 418–422 (1999).
Yu, R., Lu, W., Chen, J., McCabe, C. J. & Melmed, S. Overexpressed pituitary tumor-transforming gene causes aneuploidy in live human cells. Endocrinology 144, 4991–4998 (2003).
Yu, R., Heaney, A. P., Lu, W., Chen, J. & Melmed, S. Pituitary tumor transforming gene causes aneuploidy and p53-dependent and p53-independent apoptosis. J. Biol. Chem. 275, 36502–36505 (2000).
Bernal, J. A. et al. Proliferative potential after DNA damage and non-homologous end joining are affected by loss of securin. Cell Death Differ. 15, 202–212 (2008).
Kim, D. S. et al. Securin induces genetic instability in colorectal cancer by inhibiting double-stranded DNA repair activity. Carcinogenesis 28, 749–759 (2007).
Kim, D. et al. Pituitary tumour transforming gene (PTTG) induces genetic instability in thyroid cells. Oncogene 24, 4861–4866 (2005).
Hayward, B. E. et al. Imprinting of the G(s)alpha gene GNAS1 in the pathogenesis of acromegaly. J. Clin. Invest. 107, R31–R36 (2001).
Landis, C. A. et al. GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature 340, 692–696 (1989).
Landis, C. A. et al. Clinical characteristics of acromegalic patients whose pituitary tumors contain mutant Gs protein. J. Clin. Endocrinol. Metab. 71, 1416–1420 (1990).
Bertherat, J., Chanson, P. & Montminy, M. The cyclic adenosine 3′, 5′-monophosphate-responsive factor CREB is constitutively activated in human somatotroph adenomas. Mol. Endocrinol. 9, 777–783 (1995).
Weinstein, L. S. et al. Activating mutations of the stimulatory G. protein in the McCune–Albright syndrome. N. Engl. J. Med. 325, 1688–1695 (1991).
Lania, A. G. et al. Evolution of an aggressive prolactinoma into a growth hormone secreting pituitary tumor coincident with GNAS gene mutation. J. Clin. Endocrinol. Metab. 95, 13–17 (2010).
Ezzat, S., Zheng, L., Zhu, X. F., Wu, G. E. & Asa, S. L. Targeted expression of a human pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis. J. Clin. Invest. 109, 69–78 (2002).
Theodoropoulou, M. et al. Expression of epidermal growth factor receptor in neoplastic pituitary cells: evidence for a role in corticotropinoma cells. J. Endocrinol. 183, 385–394 (2004).
Vlotides, G. et al. Heregulin regulates prolactinoma gene expression. Cancer Res. 69, 4209–4216 (2009).
Missale, C. et al. Nerve growth factor suppresses the transforming phenotype of human prolactinomas. Proc. Natl Acad. Sci. USA 90, 7961–7965 (1993).
Shorts-Cary, L. et al. Bone morphogenetic protein and retinoic acid-inducible neural specific protein-3 is expressed in gonadotrope cell pituitary adenomas and induces proliferation, migration, and invasion. Endocrinology 148, 967–975 (2007).
Onofri, C. et al. Localization of vascular endothelial growth factor (VEGF) receptors in normal and adenomatous pituitaries: detection of a non-endothelial function of VEGF in pituitary tumours. J. Endocrinol. 191, 249–261 (2006).
Dworakowska, D. et al. Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors. Endocr. Relat. Cancer 16, 1329–1338 (2009).
Elston, M. S. et al. Wnt pathway inhibitors are strongly down-regulated in pituitary tumors. Endocrinology 149, 1235–1242 (2008).
Miyakoshi, T. et al. Expression of Wnt4 in human pituitary adenomas regulates activation of the beta-catenin-independent pathway. Endocr. Pathol. 19, 261–273 (2008).
Fan, X. et al. Gonadotropin-positive pituitary tumors accompanied by ovarian tumors in aging female ERbeta-/- mice. Proc. Natl Acad. Sci. USA 107, 6453–6458 (2010).
Manoranjan, B. et al. Estrogen receptors alpha and beta immunohistochemical expression: clinicopathological correlations in pituitary adenomas. Anticancer Res. 30, 2897–2904 (2010).
Ezzat, S. Epigenetic control in pituitary tumors. Endocr. J. 55, 951–957 (2008).
Rubinek, T. et al. The cell adhesion molecules N-cadherin and neural cell adhesion molecule regulate human growth hormone: a novel mechanism for regulating pituitary hormone secretion. J. Clin. Endocrinol. Metab. 88, 3724–3730 (2003).
Paez-Pereda, M. et al. Involvement of bone morphogenetic protein 4 (BMP-4) in pituitary prolactinoma pathogenesis through a Smad/estrogen receptor crosstalk. Proc. Natl Acad. Sci. USA 100, 1034–1039 (2003).
Jin, L. et al. Transforming growth factor-beta, transforming growth factor-beta receptor II, and p27Kip1 expression in nontumorous and neoplastic human pituitaries. Am. J. Pathol. 151, 509–519 (1997).
Auernhammer, C. J. & Melmed, S. Leukemia-inhibitory factor-neuroimmune modulator of endocrine function. Endocr. Rev. 21, 313–345 (2000).
Arzt, E. gp130 cytokine signaling in the pituitary gland: a paradigm for cytokine-neuro-endocrine pathways. J. Clin. Invest. 108, 1729–1733 (2001).
Fedele, M. et al. Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas. Oncogene 21, 3190–3198 (2002).
Fedele, M. et al. HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity. Cancer Cell 9, 459–471 (2006).
Qian, Z. R. et al. Overexpression of HMGA2 relates to reduction of the let-7 and its relationship to clinicopathological features in pituitary adenomas. Mod. Pathol. 22, 431–441 (2009).
De Martino, I. et al. HMGA proteins up-regulate CCNB2 gene in mouse and human pituitary adenomas. Cancer Res. 69, 1844–1850 (2009).
Dudley, K. J., Revill, K., Whitby, P., Clayton, R. N. & Farrell, W. E. Genome-wide analysis in a murine Dnmt1 knockdown model identifies epigenetically silenced genes in primary human pituitary tumors. Mol. Cancer Res. 6, 1567–1574 (2008).
Zhang, H. Y. et al. RUNX1 and RUNX2 upregulate Galectin-3 expression in human pituitary tumors. Endocrine 35, 101–111 (2009).
Pagotto, U. et al. The expression of the antiproliferative gene ZAC is lost or highly reduced in nonfunctioning pituitary adenomas. Cancer Res. 60, 6794–6799 (2000).
Theodoropoulou, M. et al. Tumor ZAC1 expression is associated with the response to somatostatin analog therapy in patients with acromegaly. Int. J. Cancer 125, 2122–2126 (2009).
Zhang, X. et al. Loss of expression of GADD45 gamma, a growth inhibitory gene, in human pituitary adenomas: implications for tumorigenesis. J. Clin. Endocrinol. Metab. 87, 1262–1267 (2002).
Zhang, X. et al. Maternally expressed gene 3 (MEG3) noncoding ribonucleic acid: isoform structure, expression, and functions. Endocrinology 151, 939–947 (2010).
Ezzat, S., Yu, S. & Asa, S. L. The zinc finger Ikaros transcription factor regulates pituitary growth hormone and prolactin gene expression through distinct effects on chromatin accessibility. Mol. Endocrinol. 19, 1004–1011 (2005).
Ezzat, S. et al. Ikaros integrates endocrine and immune system development. J. Clin. Invest. 115, 1021–1029 (2005).
Revill, K., Dudley, K. J., Clayton, R. N., McNicol, A. M. & Farrell, W. E. Loss of neuronatin expression is associated with promoter hypermethylation in pituitary adenoma. Endocr. Relat. Cancer 16, 537–548 (2009).
Fusco, A. MicroRNAs: a great challenge for the diagnosis and therapy of endocrine cancers. Endocr. Relat. Cancer 17, E3–E4 (2010).
Amaral, F. C. et al. MicroRNAs differentially expressed in ACTH-secreting pituitary tumors. J. Clin. Endocrinol. Metab. 94, 320–323 (2009).
Stilling, G. et al. MicroRNA expression in ACTH-producing pituitary tumors: up-regulation of microRNA-122 and -493 in pituitary carcinomas. Endocrine 38, 67–75 (2010).
Bottoni, A. et al. Identification of differentially expressed microRNAs by microarray: a possible role for microRNA genes in pituitary adenomas. J. Cell Physiol. 210, 370–377 (2007).
Butz, H. et al. Down-regulation of Wee1 kinase by a specific subset of microRNA in human sporadic pituitary adenomas. J. Clin. Endocrinol. Metab. 95, E181–E191 (2010).
Elston, M. S., McDonald, K. L., Clifton-Bligh, R. J. & Robinson, B. G. Familial pituitary tumor syndromes. Nat. Rev. Endocrinol. 5, 453–461 (2009).
Marx, S. J. et al. Multiple endocrine neoplasia type 1: clinical and genetic features of the hereditary endocrine neoplasias. Recent Prog. Horm. Res. 54, 397–438 (1999).
Pellegata, N. S. et al. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc. Natl Acad. Sci. USA 103, 15558–15563 (2006).
Igreja, S. et al. Assessment of p27 (cyclin-dependent kinase inhibitor 1B) and aryl hydrocarbon receptor-interacting protein (AIP) genes in multiple endocrine neoplasia (MEN1) syndrome patients without any detectable MEN1 gene mutations. Clin. Endocrinol. (Oxf.) 70, 259–264 (2009).
Georgitsi, M. et al. Germline CDKN1B/p27Kip1 mutation in multiple endocrine neoplasia. J. Clin. Endocrinol. Metab. 92, 3321–3325 (2007).
Molatore, S. & Pellegata, N. S. The MENX syndrome and p27: relationships with multiple endocrine neoplasia. Prog. Brain Res. 182, 295–320 (2010).
Agarwal, S. K., Mateo, C. M. & Marx, S. J. Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states. J. Clin. Endocrinol. Metab. 94, 1826–1834 (2009).
Boikos, S. A. & Stratakis, C. A. Carney complex: the first 20 years. Curr. Opin. Oncol. 19, 24–29 (2007).
Yin, Z., Williams-Simons, L., Parlow, A. F., Asa, S. & Kirschner, L. S. Pituitary-specific knockout of the Carney complex gene Prkar1a leads to pituitary tumorigenesis. Mol. Endocrinol. 22, 380–387 (2008).
Gadelha, M. R. et al. Loss of heterozygosity on chromosome 11q13 in two families with acromegaly/gigantism is independent of mutations of the multiple endocrine neoplasia type I gene. J. Clin. Endocrinol. Metab. 84, 249–256 (1999).
Georgitsi, M. et al. Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein gene mutations. Proc. Natl Acad. Sci. USA 104, 4101–4105 (2007).
Vierimaa, O. et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 312, 1228–1230 (2006).
Daly, A. F. et al. Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. J. Clin. Endocrinol. Metab. 92, 1891–1896 (2007).
Leontiou, C. A. et al. The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. J. Clin. Endocrinol. Metab. 93, 2390–2401 (2008).
Georgitsi, M. et al. Large genomic deletions in AIP in pituitary adenoma predisposition. J. Clin. Endocrinol. Metab. 93, 4146–4151 (2008).
Vargiolu, M. et al. The tyrosine kinase receptor RET interacts in vivo with aryl hydrocarbon receptor-interacting protein to alter survivin availability. J. Clin. Endocrinol. Metab. 94, 2571–2578 (2009).
Raitila, A. et al. Mice with inactivation of aryl hydrocarbon receptor-interacting protein (Aip) display complete penetrance of pituitary adenomas with aberrant ARNT expression. Am. J. Pathol. 177, 1969–1976 (2010).
Heliovaara, E. et al. The expression of AIP-related molecules in elucidation of cellular pathways in pituitary adenomas. Am. J. Pathol. 175, 2501–2507 (2009).
Chahal, H. S., Chapple, J. P., Frohman, L. A., Grossman, A. B. & Korbonits, M. Clinical, genetic and molecular characterization of patients with familial isolated pituitary adenomas (FIPA). Trends Endocrinol. Metab. 21, 419–427 (2010).
Farrell, W. E. Pituitary tumours: findings from whole genome analyses. Endocr. Relat. Cancer 13, 707–716 (2006).
Farrell, W. E. & Clayton, R. N. Epigenetic change in pituitary tumorigenesis. Endocr. Relat. Cancer 10, 323–330 (2003).
Sharpless, N. E. & DePinho, R. A. Telomeres, stem cells, senescence, and cancer. J. Clin. Invest. 113, 160–168 (2004).
Schmitt, C. A. et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 109, 335–346 (2002).
Campisi, J. Suppressing cancer: the importance of being senescent. Science 309, 886–887 (2005).
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D. & Lowe, S. W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88, 593–602 (1997).
Bartkova, J. et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 444, 633–637 (2006).
Vlotides, G., Eigler, T. & Melmed, S. Pituitary tumor-transforming gene: physiology and implications for tumorigenesis. Endocr. Rev. 28, 165–186 (2007).
Chesnokova, V., Kovacs, K., Castro, A. V., Zonis, S. & Melmed, S. Pituitary hypoplasia in Pttg−/− mice is protective for Rb+/− pituitary tumorigenesis. Mol. Endocrinol. 19, 2371–2379 (2005).
Chesnokova, V. et al. Senescence mediates pituitary hypoplasia and restrains pituitary tumor growth. Cancer Res. 67, 10564–10572 (2007).
Uccella, S. et al. Aneuploidy, centrosome alteration and securin overexpression as features of pituitary somatotroph and lactotroph adenomas. Anal. Quant. Cytol. Histol. 27, 241–252 (2005).
Chesnokova, V. et al. p21(Cip1) restrains pituitary tumor growth. Proc. Natl Acad. Sci. USA 105, 17498–17503 (2008).
Fukuoka, H. et al. HER2/ErbB2 receptor signaling in rat and human prolactinoma cells: strategy for targeted prolactinoma therapy. Mol. Endocrinol. 25, 92–103 (2011).
Fougner, S. L. et al. The expression of E-cadherin in somatotroph pituitary adenomas is related to tumor size, invasiveness, and somatostatin analog response. J. Clin. Endocrinol. Metab. 95, 2334–2342 (2010).
Pertuit, M., Barlier, A., Enjalbert, A. & Gerard, C. Signalling pathway alterations in pituitary adenomas: involvement of Gsalpha, cAMP and mitogen-activated protein kinases. J. Neuroendocrinol. 21, 869–877 (2009).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Melmed, S. Pathogenesis of pituitary tumors. Nat Rev Endocrinol 7, 257–266 (2011). https://doi.org/10.1038/nrendo.2011.40
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2011.40
This article is cited by
-
The role of preoperative MRI in endoscopic transnasal transsphenoidal hypophysectomy of pituitary adenoma
European Archives of Oto-Rhino-Laryngology (2024)
-
Clinical situations for which 3D printing is considered an appropriate representation or extension of data contained in a medical imaging examination: neurosurgical and otolaryngologic conditions
3D Printing in Medicine (2023)
-
Epidemiology of common and uncommon adult pituitary tumors in the U.S. according to the 2017 World Health Organization classification
Pituitary (2022)
-
The microenvironment of pituitary adenomas: biological, clinical and therapeutical implications
Pituitary (2022)